Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$20 Mln
P/E Ratio
--
P/B Ratio
2.25
Industry P/E
--
Debt to Equity
--
ROE
-0.71 %
ROCE
-53.55 %
Div. Yield
0 %
Book Value
2.45
EPS
-2.62
CFO
$-124.24 Mln
EBITDA
$-136.06 Mln
Net Profit
$-200.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Pulmatrix (PULM)
| -9.54 | -25.36 | 2.84 | 197.84 | 2.11 | -29.16 | -43.40 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Pulmatrix (PULM)
| 271.24 | -52.06 | -63.23 | 38.37 | -64.18 | -82.81 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an... engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts. Address: 945 Concord Street, Framingham, MA, United States, 01701 Read more
President, CEO & Director
Mr. Teofilo David Raad MBA
President, CEO & Director
Mr. Teofilo David Raad MBA
Headquarters
Bedford, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Pulmatrix Inc (PULM) stood at $ 10 Mln as on 31-Dec-24
The share price of Pulmatrix Inc (PULM) is $6.31 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Pulmatrix Inc (PULM) has given a return of 2.11% in the last 3 years.
Pulmatrix Inc (PULM) has a market capitalisation of $ 20 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Pulmatrix Inc (PULM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Pulmatrix Inc (PULM) and enter the required number of quantities and click on buy to purchase the shares of Pulmatrix Inc (PULM).
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts. Address: 945 Concord Street, Framingham, MA, United States, 01701
The CEO & director of Mr. Teofilo David Raad MBA. is Pulmatrix Inc (PULM), and CFO & Sr. VP is Mr. Teofilo David Raad MBA.
There is no promoter pledging in Pulmatrix Inc (PULM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Pulmatrix Inc. (PULM) | Ratios |
|---|---|
|
Return on equity(%)
|
-70.96
|
|
Operating margin(%)
|
-91.53
|
|
Net Margin(%)
|
-122.46
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Pulmatrix Inc (PULM) was $0 Mln.
$0.80
(
